Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer
Clinical trial NCT02392611 · COMPLETED
Trial details
- NCT number
- NCT02392611
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-16
- Primary completion
- 2017-10-11
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.